论文部分内容阅读
目的探讨麝香保心丸联合曲美他嗪治疗冠心病介入术后残余胸痛的临床可行性。方法选取我院112例冠心病介入术后残余胸痛患者进行分组研究,随机分为观察组和对照组,每组56例患者。对照组采用常规抗缺血及抗栓调脂进行治疗,观察组在此基础上增加麝香保心丸联合曲美他嗪的治疗,对比两组治疗效果。结果观察组治疗后不同时期的VAS评分显著低于对照组,差异有统计学意义(P<0.05);治疗有效率(98.21%)高于对照组(87.50%),差异有统计学意义(P<0.05)。结论采取麝香保心丸联合曲美他嗪治疗冠心病介入术后残余胸痛患者效果显著,有利于促进患者早日康复。
Objective To investigate the clinical feasibility of using Shexiang Baoxin Pill combined with trimetazidine in the treatment of residual chest pain after coronary intervention. Methods A total of 112 patients with residual chest pain after coronary intervention in our hospital were divided into two groups and randomly divided into observation group and control group with 56 patients in each group. The control group was treated with conventional anti-ischemic and antithrombotic lipid-lowering therapy. On the basis of this study, the observation group was given the drug of Shexiang Baoxin Pill combined with trimetazidine, and the treatment effect was compared between the two groups. Results The VAS score of observation group at different stages after treatment was significantly lower than that of control group (P <0.05), and the effective rate of treatment (98.21%) was higher than that of control group (87.50%) (P <0.05). Conclusion Shexiang Baoxin Pills combined with trimetazidine treatment of residual chest pain after coronary intervention in patients with significant effect, is conducive to promoting early recovery of patients.